Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Xlife Sciences AG paid€0.00 Mil more to buy back shares than it received from issuing new shares.
It spent€3.01 Mil paying down its debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It received€3.16 Mil on other financial activities.
In all, Xlife Sciences AGearned€0.15 Mil on financial activities for the
six
months ended in Dec. 2025.
Xlife Sciences AG (FRA:XLS) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Xlife Sciences AG's issuance of stock for the
six
months ended in Dec. 2025 was €0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Xlife Sciences AG's repurchase of stock for the
six
months ended in Dec. 2025 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Xlife Sciences AG's net issuance of debt for the
six
months ended in Dec. 2025 was €-3.01 Mil.
Xlife Sciences AG spent€3.01 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Xlife Sciences AG's net issuance of preferred for the
six
months ended in Dec. 2025 was €0.00 Mil.
Xlife Sciences AG paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Xlife Sciences AG's cash flow for dividends for the
six
months ended in Dec. 2025 was €0.00 Mil.
Xlife Sciences AG received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Xlife Sciences AG's other financing for the
six
months ended in Dec. 2025 was €3.16 Mil.
Xlife Sciences AG received€3.16 Mil on other financial activities.
Xlife Sciences AG Cash Flow from Financing Related Terms
Xlife Sciences AG Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Xlife Sciences AG's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €2.91 Mil mean?
Xlife Sciences AG (FRA:XLS) has a Cash Flow from Financing of €2.91 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Cash Flow from Financing too high?
Xlife Sciences AG's current Cash Flow from Financing is €2.91 Mil. Overall, Xlife Sciences AG has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Cash Flow from Financing compare to VRTX and REGN?
Xlife Sciences AG's Cash Flow from Financing of €2.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Xlife Sciences AG and its competitors. Xlife Sciences AG's current Cash Flow from Financing is €2.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.63, compared to a current price of €19.20 — trading 151.6% above its estimated fair value. The current Cash Flow from Financing is €2.91 Mil. Xlife Sciences AG's overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current Cash Flow from Financing is €2.91 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of €19.20 is trading 151.6% above its estimated GF Value™ of €7.63.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for FRA:XLS:
Cash Flow from Financing: €2.91 Mil
GF Value™: €7.63 vs. price of €19.20 (151.6% above fair value)
No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
47GF Score
Get the complete analysis for FRA:XLS
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XLS has been successfully added to your 
